{"id":7712,"date":"2022-02-08T20:18:41","date_gmt":"2022-02-08T19:18:41","guid":{"rendered":"https:\/\/irlab.se\/new-investors\/"},"modified":"2022-02-15T18:54:30","modified_gmt":"2022-02-15T17:54:30","slug":"new-investors","status":"publish","type":"page","link":"https:\/\/irlab.se\/sv\/new-investors\/","title":{"rendered":"New Investors"},"content":{"rendered":"\n
\n
\n
\n
IRLAB A<\/div>\n
1.488<\/div>\n
SEK<\/div>\n <\/div>\n\n
\n
\n
\n
TODAY<\/div>\n
-3.25 %<\/div>\n <\/div>\n\n
\n
TODAY SEK<\/div>\n
-0.05 SEK<\/div>\n\n <\/div>\n\n
\n
16:00:00<\/div>\n
2026-04-28<\/div>\n <\/div>\n <\/div>\n <\/div>\n\n
\n
\n
\n\n\n
\n
YEAR LOW<\/div>\n
1.31 SEK<\/div>\n <\/div>\n\n
\n
YEAR HIGH<\/div>\n
2.145 SEK<\/div>\n <\/div>\n <\/div>\n
\n
\n
ATH:<\/div>\n
102.05 SEK<\/div>\n <\/div>\n\n
\n
MCAP: <\/div>\n
126 MSEK<\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n\n<\/div>\n\n \n\n\n
<\/div>\n\n\n\n
\n
\n

CEO COMMENTS<\/p>\n\n\n\n

Nicholas Waters comments the third quarter 2021<\/h3>\n\n\n\n

For the third quarter of 2021 IRLAB has shown a positive result of SEK 120m, primarily due to the licensing of our drug candidate mesdopetam to Ipsen, a global pharmaceutical firm. The mesdopetam deal is transformational for IRLAB \u2013 we have shown that our business model works and that our ISP research platform is an effective tool for developing drug candidates that are attractive to the market. <\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure><\/div>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n

SENASTE RAPPORTERNA<\/h2>\n\n\n\n
\n
\n

Q3<\/h2>\n\n\n\n

Del\u00e5rsrapport ><\/a><\/p>\n\n\n\n

CEO comments ><\/p>\n\n\n\n

Presentation ><\/p>\n\n\n\n

Q3 Webcast ><\/p>\n<\/div>\n\n\n\n

\n

Q2<\/h2>\n\n\n\n

Del\u00e5rsrapport ><\/p>\n\n\n\n

CEO comments ><\/p>\n\n\n\n

Presentation ><\/p>\n\n\n\n

Q3 Webcast ><\/p>\n<\/div>\n\n\n\n

\n

2020<\/h2>\n\n\n\n

\u00c5rsrapport ><\/p>\n\n\n\n

CEO comments ><\/p>\n\n\n\n

Presentation ><\/p>\n\n\n\n

2020 Webcast ><\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n
\n
\n\n
\n SENASTE PRESSRELEASEN<\/span>\n <\/div>\n \n
\n See all pressreleases > <\/span><\/a>\n <\/div>\n \n <\/div>\n<\/div>\n\n\n
<\/div>\n\n\n\n
\"\"<\/figure>\n\n\n\n
<\/div>\n\n\n\n
\n
\n
\n
\n SENASTE PRESENTATIONEN <\/div>\n \n
\n \n\t\t\t\t\t\t\t\t\t25 MAJ 2021 \t\t\t\t\t\t\t\t<\/span>\n

IRLAB:s l\u00e4kemedelskandidat mesdopetams Fas I- resultat publicerade i vetenskapliga tidskriften PR&P<\/h3>\n\n

IRLAB (Nasdaq Stockholm: IRLAB A) meddelade idag att en vetenskaplig artikel som beskriver resultaten f\u00f6r den kliniska fas I-studien med l\u00e4kemedelskandidaten mesdopetam har publicerats i tidskriften Pharmacology Research & Perspectives (PR&P). Mesdopetam \u00e4r en dopamin D3-receptorantagonist som nu utv\u00e4rderas i en internationell Fas IIb\/III-studie f\u00f6r behandling av levodopa-inducerade dyskinesier (LIDs) vid Parkinsons sjukdom.<\/p>\n\n L\u00e4s mer ><\/a>\n <\/div>\n\n \n\n \n <\/div>\n<\/div><\/div>\n\n\n\n

\n

FINANSIELL KALENDER<\/h2>\n\n\n\n

KOMMANDE<\/p>\n\n\n\n

23 FEBRUARI 2022<\/h3>\n\n\n\n

BOKSLUTSKOMMUNIK\u00c9<\/p>\n\n\n\n

N\u00c4STKOMMANDE<\/p>\n\n\n\n

4-8 APRIL, 2022<\/h3>\n\n\n\n

\u00c5RSREDOVISNING<\/p>\n\n\n\n

11 MAJ 2022<\/h3>\n\n\n\n

\u00c5RSST\u00c4MMA<\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CEO COMMENTS Nicholas Waters comments the third quarter 2021 For the third quarter of 2021 IRLAB has shown a positive result of SEK 120m, primarily due to the licensing of our drug candidate mesdopetam to Ipsen, a global pharmaceutical firm. The mesdopetam deal is transformational for IRLAB \u2013 we have shown that our business model […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-7712","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nNew Investors - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/sv\/new-investors\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Investors - IRLAB\" \/>\n<meta property=\"og:description\" content=\"CEO COMMENTS Nicholas Waters comments the third quarter 2021 For the third quarter of 2021 IRLAB has shown a positive result of SEK 120m, primarily due to the licensing of our drug candidate mesdopetam to Ipsen, a global pharmaceutical firm. The mesdopetam deal is transformational for IRLAB \u2013 we have shown that our business model […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/sv\/new-investors\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta property=\"article:modified_time\" content=\"2022-02-15T17:54:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/irlab.se\/wp-content\/uploads\/2022\/02\/CEO_Nocholas_Waters_800.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irlab.se\/sv\/new-investors\/\",\"url\":\"https:\/\/irlab.se\/sv\/new-investors\/\",\"name\":\"New Investors - IRLAB\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/irlab.se\/sv\/new-investors\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/irlab.se\/sv\/new-investors\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/irlab.se\/wp-content\/uploads\/2022\/02\/CEO_Nocholas_Waters_800.jpg\",\"datePublished\":\"2022-02-08T19:18:41+00:00\",\"dateModified\":\"2022-02-15T17:54:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/irlab.se\/sv\/new-investors\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irlab.se\/sv\/new-investors\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\/\/irlab.se\/sv\/new-investors\/#primaryimage\",\"url\":\"https:\/\/irlab.se\/wp-content\/uploads\/2022\/02\/CEO_Nocholas_Waters_800.jpg\",\"contentUrl\":\"https:\/\/irlab.se\/wp-content\/uploads\/2022\/02\/CEO_Nocholas_Waters_800.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irlab.se\/sv\/new-investors\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irlab.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Investors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irlab.se\/#website\",\"url\":\"https:\/\/irlab.se\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson's disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irlab.se\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Investors - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/sv\/new-investors\/","og_locale":"sv_SE","og_type":"article","og_title":"New Investors - IRLAB","og_description":"CEO COMMENTS Nicholas Waters comments the third quarter 2021 For the third quarter of 2021 IRLAB has shown a positive result of SEK 120m, primarily due to the licensing of our drug candidate mesdopetam to Ipsen, a global pharmaceutical firm. The mesdopetam deal is transformational for IRLAB \u2013 we have shown that our business model […]","og_url":"https:\/\/irlab.se\/sv\/new-investors\/","og_site_name":"IRLAB","article_modified_time":"2022-02-15T17:54:30+00:00","og_image":[{"url":"https:\/\/irlab.se\/wp-content\/uploads\/2022\/02\/CEO_Nocholas_Waters_800.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/irlab.se\/sv\/new-investors\/","url":"https:\/\/irlab.se\/sv\/new-investors\/","name":"New Investors - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"primaryImageOfPage":{"@id":"https:\/\/irlab.se\/sv\/new-investors\/#primaryimage"},"image":{"@id":"https:\/\/irlab.se\/sv\/new-investors\/#primaryimage"},"thumbnailUrl":"https:\/\/irlab.se\/wp-content\/uploads\/2022\/02\/CEO_Nocholas_Waters_800.jpg","datePublished":"2022-02-08T19:18:41+00:00","dateModified":"2022-02-15T17:54:30+00:00","breadcrumb":{"@id":"https:\/\/irlab.se\/sv\/new-investors\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/sv\/new-investors\/"]}]},{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/irlab.se\/sv\/new-investors\/#primaryimage","url":"https:\/\/irlab.se\/wp-content\/uploads\/2022\/02\/CEO_Nocholas_Waters_800.jpg","contentUrl":"https:\/\/irlab.se\/wp-content\/uploads\/2022\/02\/CEO_Nocholas_Waters_800.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/sv\/new-investors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"New Investors"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson's disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/pages\/7712","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/comments?post=7712"}],"version-history":[{"count":4,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/pages\/7712\/revisions"}],"predecessor-version":[{"id":7784,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/pages\/7712\/revisions\/7784"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=7712"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}